Prevention timed to the season
In the Sahel and parts of eastern and southern Africa, most malaria occurs during a short, intense rainy season. Seasonal malaria chemoprevention (SMC) means giving children a full curative course of antimalarial medicine every month during that season — whether or not they are infected — to clear existing infections and block new ones during the period of greatest risk.
The WHO recommendation
WHO gives SMC a strong recommendation: in areas of seasonal malaria transmission, children in the age groups at high risk of severe malaria should receive antimalarial medicines during peak transmission seasons. The standard regimen is sulfadoxine-pyrimethamine + amodiaquine (SP+AQ), delivered as monthly cycles — typically 3 to 5 cycles per season depending on local transmission length.
Key design points for programs
- Drug choice: WHO recommends a combination different from the country's first-line treatment, with well-matched pharmacology — which is why SP+AQ is used for SMC even where an ACT is first-line treatment.
- Age coverage: the classic target is children 3–59 months; evidence now also supports including children 60–120 months in some settings.
- Delivery: door-to-door community distribution achieves the highest coverage; each cycle is directly observed where possible.
- Resistance watch: SMC is not recommended where SP+AQ resistance is high — programs monitor molecular markers.
Procurement notes
SMC campaigns are volume-driven and time-critical: programs order full seasons of co-packaged SP+AQ blister courses months ahead of the rains. When sourcing, confirm co-blister packaging, pediatric-friendly formulation, and delivery lead times aligned to the transmission calendar.
Frequently asked questions
What drugs are used for SMC?
A monthly full course of sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ), given during the peak transmission season regardless of whether the child is infected.
Who receives SMC?
Children in the age groups at highest risk of severe malaria in areas of seasonal transmission — classically 3–59 months, with WHO guidance also covering older children up to 10 years in some settings.
Source: summarised in plain language from the WHO guidelines for malaria (10 September 2026), World Health Organization. This guide is for buyer education only — clinical decisions must follow the locally approved product insert and national treatment guidelines.
Artemisine Medicines